AU2005214115B2 - Galanin receptors and brain injury - Google Patents

Galanin receptors and brain injury Download PDF

Info

Publication number
AU2005214115B2
AU2005214115B2 AU2005214115A AU2005214115A AU2005214115B2 AU 2005214115 B2 AU2005214115 B2 AU 2005214115B2 AU 2005214115 A AU2005214115 A AU 2005214115A AU 2005214115 A AU2005214115 A AU 2005214115A AU 2005214115 B2 AU2005214115 B2 AU 2005214115B2
Authority
AU
Australia
Prior art keywords
galr2
galanin
disease
specific agonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005214115A
Other languages
English (en)
Other versions
AU2005214115A1 (en
Inventor
David Wynick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotargets Ltd
Original Assignee
Neurotargets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd
Publication of AU2005214115A1 publication Critical patent/AU2005214115A1/en
Application granted granted Critical
Publication of AU2005214115B2 publication Critical patent/AU2005214115B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
AU2005214115A 2004-02-17 2005-01-18 Galanin receptors and brain injury Ceased AU2005214115B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403509.3 2004-02-17
GBGB0403509.3A GB0403509D0 (en) 2004-02-17 2004-02-17 Galanin receptors and brain injury
PCT/GB2005/000188 WO2005080427A1 (en) 2004-02-17 2005-01-18 Galanin receptors and brain injury

Publications (2)

Publication Number Publication Date
AU2005214115A1 AU2005214115A1 (en) 2005-09-01
AU2005214115B2 true AU2005214115B2 (en) 2010-08-12

Family

ID=32039889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005214115A Ceased AU2005214115B2 (en) 2004-02-17 2005-01-18 Galanin receptors and brain injury

Country Status (8)

Country Link
US (2) US20080020975A1 (enExample)
EP (1) EP1723175A1 (enExample)
JP (1) JP2008501632A (enExample)
CN (1) CN1922205A (enExample)
AU (1) AU2005214115B2 (enExample)
CA (1) CA2555550A1 (enExample)
GB (1) GB0403509D0 (enExample)
WO (1) WO2005080427A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809619A1 (en) 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
AU2008207287A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
WO2009079078A1 (en) 2007-12-14 2009-06-25 Labogroup S.A.S. Delivering aerosolizable food products
CN108404115A (zh) 2010-10-15 2018-08-17 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
EP2821081A1 (en) * 2013-07-05 2015-01-07 ResuSciTec GmbH Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
KR101514440B1 (ko) * 2013-12-13 2015-04-22 고려대학교 산학협력단 갈라닌 수용체 3형의 리간드로서 스펙신의 용도
US10314911B2 (en) * 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
KR101885238B1 (ko) * 2015-11-30 2018-08-06 주식회사 뉴라클사이언스 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도
CN106880837A (zh) * 2015-12-15 2017-06-23 北京脑重大疾病研究院 一种甘丙肽在制备防止缺血性脑卒的试剂中的应用
ES2707210B2 (es) * 2017-10-02 2020-09-30 Univ Malaga GAL(1-15) y análogos de la misma para uso en la prevención y/o tratamiento de trastornos y efectos relacionados con el alcohol.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003059A1 (en) * 1996-07-24 1998-01-29 University Of Bristol Galanin
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
US6337206B1 (en) * 1997-12-18 2002-01-08 Merck & Co., Inc. Nucleic acid encoding mouse galanin receptor (GALR2)
WO2002096934A1 (en) * 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
US6544753B1 (en) * 1996-12-27 2003-04-08 Merck & Co., Inc. Galanin receptor (GALR2) binding assay
US6586191B2 (en) * 1996-01-24 2003-07-01 Synaptic Pharmaceutical Corporation Method of identifying compounds that bind galanin receptor (GALR2)

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
US6586191B2 (en) * 1996-01-24 2003-07-01 Synaptic Pharmaceutical Corporation Method of identifying compounds that bind galanin receptor (GALR2)
US20030129702A1 (en) * 1996-01-24 2003-07-10 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR2 receptors and uses thereof
US20030215823A1 (en) * 1996-01-24 2003-11-20 Synaptic Pharmaceutical Corporation Uses of galanin GALR2 receptors
WO1998003059A1 (en) * 1996-07-24 1998-01-29 University Of Bristol Galanin
US6544753B1 (en) * 1996-12-27 2003-04-08 Merck & Co., Inc. Galanin receptor (GALR2) binding assay
US6337206B1 (en) * 1997-12-18 2002-01-08 Merck & Co., Inc. Nucleic acid encoding mouse galanin receptor (GALR2)
WO2002096934A1 (en) * 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, H-X ET AL., PNAS. 2001, vol. 98, no. 17, pages 9960-9964 *

Also Published As

Publication number Publication date
US20100184638A1 (en) 2010-07-22
CA2555550A1 (en) 2005-09-01
CN1922205A (zh) 2007-02-28
GB0403509D0 (en) 2004-03-24
US20080020975A1 (en) 2008-01-24
AU2005214115A1 (en) 2005-09-01
JP2008501632A (ja) 2008-01-24
WO2005080427A1 (en) 2005-09-01
EP1723175A1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
US20100184638A1 (en) Galanin Receptors and Brain Injury
Keverne Importance of olfactory and vomeronasal systems for male sexual function
Chapman et al. Tbx6, a mouse T-Box gene implicated in paraxial mesoderm formation at gastrulation
JP2000506392A (ja) 新規なヒト代謝指向型グルタミン酸レセプター
JP2001514879A (ja) カプサイシン受容体およびカプサイシン受容体関連ポリペプチドをコードする核酸配列ならびにその使用
de Roux GnRH receptor and GPR54 inactivation in isolated gonadotropic deficiency
Tong et al. Comparative developmental profile of the neuropeptide Y Y1 receptor gene and protein in the rat brain
US20090298770A1 (en) Mammalian relaxin receptors
KR20050042826A (ko) 쥐피알54 넉-아웃 포유류 및 이를 이용한 스크리닝 방법
JP2003531356A (ja) プリオンタンパク質結合タンパク質及びそれらの使用
JP2002511747A (ja) 耐糖能障害疾患に対する治療および診断ツール
Stevens et al. Nociceptin produces antinociception after spinal administration in amphibians
JP2004520017A (ja) 受容体
JP2007530069A6 (ja) イオンチャネル
JP2007530069A (ja) イオンチャネル
US20090048200A1 (en) GPR 26 G-Protein Coupled Receptor
JP5064398B2 (ja) Ｇｐｒ１４６レセプター
Klugman Uncovering a novel role for BIRC6 in a dwarf mutant mouse
JP4926952B2 (ja) Ｇｐｒ８６受容体の使用
US20100158807A1 (en) Receptor
US20100272647A1 (en) Receptor
WO2002088183A2 (en) G-protein coupled receptor
Wu Hormone control of male development and behavior
Wang Genetic and phenotypic analysis of Tcm, a mutation affecting early embryonic eye development
EP1874814A1 (en) Ion chann

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired